S2G invests NOK 250 million in Oxzo to expand oxygenation technology in aquaculture.
Oxzo has added S2G Investments as a shareholder through a NOK 250 million transaction ($24.75 million/€21.25 million).
Oxzo supplies oxygenation, aeration and ozone systems for aquaculture. Its products include the Oxymar platforms and the Oxymovil mobile oxygen units, which are used by several Norwegian salmon producers. The company is headquartered in Chile.
“The entry of S2G as a co-owner marks a turning point for us,” said Svein Arve Tronsgård, business development director at Oxzo Technologies Norway AS. “For the team in Norway, this strengthens the potential to scale our oxygenation solutions in the major salmon-producing regions of the North Atlantic.”
Oxzo says independent studies from Chile show higher biomass, reduced costs and lower mortality when using its systems.
“We see aquaculture as a cornerstone of the global protein system that must grow in line with demand while protecting marine environments,” said Larsen Mettler, managing director in S2G’s oceans investment team. “Oxzo’s technologies are contributing to that by improving productivity, fish welfare and ecological performance.”
Rafael Ariztía, chair of Fiordo Austral and Oxzo, said the investment supports the company’s international plans. Claudio Inglesi, partner at Altis, said S2G brings sector experience and a relevant investment track record.
According to Oxzo, the new capital will support further development of its technology and international expansion.
